Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$2.36
-$0.06(-3.31%)
At close: 4:00 PM EDT
$2.36
-$0.06(-3.31%)
Day’s Range― - ―
52-Week Range$1.52 - $24.90
Previous CloseN/A
Volume62.24K
Average Volume (3M)216.05K
Market Cap
$5.07M
Enterprise Value$109.56K
Total Cash (Recent Filing)$3.99M
Total Debt (Recent Filing)$1.82M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 05, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.46
Shares Outstanding3,316,803
10 Day Avg. Volume44,387
30 Day Avg. Volume216,048
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.61
Price to Sales (P/S)0.80
P/FCF Ratio-0.28
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.03
Enterprise Value/Gross Profit0.09
Enterprise Value/Ebitda-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.18
Revenue Forecast (FY)$6.13M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe increase in trailing revenue indicates improving commercial traction for the screening business. If sustained, greater customer adoption can expand the installed base and increase recurring cartridge demand, strengthening operating leverage as sales scale.
FDA Market ExpansionThe FDA submission creates a potential pathway from existing operations into the U.S. drug-screening market, substantially broadening the addressable customer base. Strong reported clinical metrics may support regulatory credibility, though clearance remains necessary.
Recurring Consumables ModelConsumable cartridges can generate repeat revenue after customers adopt the screening platform, making growth less dependent on one-time instrument sales. A larger installed base could therefore improve customer retention and revenue visibility as testing volumes increase.
Bears Say
Persistent UnprofitabilityThe company has not yet demonstrated a profitable operating model despite revenue growth. Deep losses reduce internal funding capacity and mean future expansion must depend on achieving meaningful scale, improving pricing or lowering costs without weakening demand.
Heavy Cash BurnPersistent and worsening cash consumption shows the business is not self-funding as it scales. Continued negative cash generation can constrain product development and commercialization, while increasing the need for additional financing before operations reach breakeven.
Equity Funding And DilutionRepeated use of equity instruments and warrant exercises expands the share base while the company remains cash-flow negative. This financing pattern can dilute existing holders and signals that ongoing operations and growth initiatives remain reliant on external capital.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions’s price range in the past 12 months?
Intelligent Bio Solutions lowest stock price was $1.52 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions’s market cap?
Intelligent Bio Solutions’s market cap is $5.07M.
When is Intelligent Bio Solutions’s upcoming earnings report date?
Intelligent Bio Solutions’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.
How were Intelligent Bio Solutions’s earnings last quarter?
Intelligent Bio Solutions released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter.
Is Intelligent Bio Solutions overvalued?
According to Wall Street analysts Intelligent Bio Solutions’s price is currently Overvalued.
Does Intelligent Bio Solutions pay dividends?
Intelligent Bio Solutions does not currently pay dividends.
What is Intelligent Bio Solutions’s EPS estimate?
Intelligent Bio Solutions’s EPS estimate is -1.31.
How many shares outstanding does Intelligent Bio Solutions have?
Intelligent Bio Solutions has 3,316,803 shares outstanding.
What happened to Intelligent Bio Solutions’s price movement after its last earnings report?
Intelligent Bio Solutions reported an EPS of -$1.8 in its last earnings report. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
2.73% Insiders
0.45% Mutual Funds
4.26% Other Institutional Investors
92.38% Public Companies and
Individual Investors